Evidence map›Paper›PMID 30997067›Full record

ArticleClinical case reports2019

Acute non-heparin-induced thrombocytopenia during hemodiafiltration in a patient with multiple myeloma.

Makiko Morita, Kayoko Nakanishi, Kenta Masuda, Kazuhiro Yoshida, Daiki Shimomura, Atsumi Ishida, Shuichi Shiga, Satoshi Ichiyama

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Makiko MoritaDepartment of Clinical Laboratory Kyoto University Hospital Kyoto Japan.ORCID https://orcid.org/0000-0003-4803-9994
Kayoko NakanishiDepartment of Clinical Laboratory Kyoto University Hospital Kyoto Japan.
Kenta MasudaDepartment of Clinical Laboratory Kyoto University Hospital Kyoto Japan.
Kazuhiro YoshidaArtificial Kidney Unit Kyoto University Hospital Kyoto Japan.
Daiki ShimomuraDepartment of Laboratory Medicine Tenri Hospital Nara Japan.
Atsumi IshidaDepartment of Clinical Laboratory Kyoto University Hospital Kyoto Japan.
Shuichi ShigaDepartment of Clinical Laboratory Kyoto University Hospital Kyoto Japan.
Satoshi IchiyamaDepartment of Clinical Laboratory Kyoto University Hospital Kyoto Japan.
Kyoto University Hospital · JPTenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report demonstrates that not only heparin-induced thrombocytopenia, but also hemodialysis conditions (platelet activation due to hemodiafiltration and heparin underdosing) may markedly reduce the platelet count and cause clotting in the hemodialysis circuit in patients in a hypercoagulable state. The clot prevention effects of bortezomib are therefore of great importance.

Indexed as

bortezomibhemodiafiltrationhemodialysisheparin‐induced thrombocytopeniaplatelet aggregation

Identifiers

PMID30997067
PMCPMC6452500
OpenAlexW2916829959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.